Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Price, Quote & News

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 980 4182

Website: quoinpharma.com

Address:

42127 Pleasant Forest Court, Ashburn, United States

MythicalDragon Jul. 28 at 9:17 PM

$QNRX

0 · Reply

Pipelinepivots Jul. 28 at 6:10 PM

PRFX deal closing any day! Opioid-free pain relief is the future and PRFX is ahead of the curve. FDA-backed tech, low float, and huge unmet demand. One trial update or partner deal and this goes vertical. Nobody’s watching… I am. $ACXP $ENSC $QNRX

0 · Reply

MarianChavis603 Jul. 24 at 3:49 PM

$QNRX develops neurological solutions, while AITX develops financial and operational solutions for a fragmented security market—with strategic debt, not dilution.

0 · Reply

StayPresent Jul. 22 at 5:53 PM

$QNRX still a pos

0 · Reply

TwongStocks Jul. 17 at 8:11 PM

$QNRX They filed the definitive proxy for the shareholder meeting on Aug 21. https://www.sec.gov/ix?doc=/Archives/edgar/data/1671502/000110465925068650/tm252555-3_def14a.htm All proposals similar to the prelim proxy that was filed on July 7 👇. Big item is Prop 2, the request to increase the authorized share capital from 100m to 5B. Record date is close of business July 16. If you held shares at close on July 16, you are eligible to vote. At the record date, there were 20,585,830 ordinary shares outstanding, represented by 588,166 ADSs.

0 · Reply

TestacularTommy Jul. 17 at 12:06 AM

$QNRX worst 7k i ever spent, down 99%, my average is $6900🤣 what a joke,from all the R/S, thought monkey pox was going to keep this alive, what a scam, people use to defend this company, iremember the dsy it shot up like 1000% ,igot smoked, been a bagger since, shuld i just sell for $7K loss this year, or try to atleast get 1k back lol idnt think its possible

0 · Reply

Trust121 Jul. 14 at 6:45 PM

$QNRX Nice uptrend, steady

0 · Reply

Thestocktraderhubzee Jul. 9 at 9:30 AM

WATCHLIST JUL 09 2025 $ASH Ashland To Close Two New Jersey Plants In $60M Manufacturing Optimization Plan, Shifting Production To Larger Sites $ATR Aptar Unveils Dual-Active Material Science Technology To Protect Sensitive Pharma And Medical Devices From Moisture And Oxygen $QNRX On July 3, 2025, Quoin Pharmaceuticals And CFO Gordon Dunn Agreed To A Mutual Separation Later This Year; Mr. Dunn Will Continue In His Current Role Until His Successor Is Appointed $AGCO AGCO Corporation And TAFE Enter Fourth Amendment To Agreement; Amendment Extends Expiration Date To November 28, 2025 $TKO Esports World Cup Foundation Taps TKO-Owned IMG To Launch 'EWC Spotlight,' Merging Competitive Gaming, Entertainment And Global Broadcast Innovation

1 · Reply

StayPresent Jul. 8 at 2:02 AM

$QNRX pos

1 · Reply

TwongStocks Jul. 7 at 10:20 PM

$QNRX Preliminary proxy filed for shareholder meeting on Aug 21st. https://www.sec.gov/ix?doc=/Archives/edgar/data/1671502/000110465925066171/tm252555-1_pre14a.htm Proposals: 1) Election of Directors 2) Approve an increase in authorized share capital from 100m to 5B. 3) Approve the Compensation Policy for Executive Officers & Directors 4) Approve the 2025 Equity Incentive Plan 5) Approve changes to the non-employee directors’ compensation program 6) Approve options grants to certain non-employee directors 7) Appoint CBIZ CPAs PC as the company's registered independent auditor

0 · Reply

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 14, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 10, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 2, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Mar 31, 2025, 4:18 AM EDT - 4 months ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 13, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 4, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 25, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 4, 2025, 7:30 AM EST - 6 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Jan 23, 2025, 8:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 5:30 AM EST - 6 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 6, 2025, 8:30 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024, 9:20 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024, 8:00 AM EST - 7 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 18, 2024, 8:18 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Oct 31, 2024, 4:05 PM EDT - 9 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Sep 9, 2024, 8:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 5:00 AM EDT - 1 year ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Dec 13, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Nov 10, 2022, 2:38 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

MythicalDragon Jul. 28 at 9:17 PM

$QNRX

0 · Reply

Pipelinepivots Jul. 28 at 6:10 PM

0 · Reply

MarianChavis603 Jul. 24 at 3:49 PM

$QNRX develops neurological solutions, while AITX develops financial and operational solutions for a fragmented security market—with strategic debt, not dilution.

0 · Reply

StayPresent Jul. 22 at 5:53 PM

$QNRX still a pos

0 · Reply

TwongStocks Jul. 17 at 8:11 PM

0 · Reply

TestacularTommy Jul. 17 at 12:06 AM

0 · Reply

Trust121 Jul. 14 at 6:45 PM

$QNRX Nice uptrend, steady

0 · Reply

Thestocktraderhubzee Jul. 9 at 9:30 AM

1 · Reply

StayPresent Jul. 8 at 2:02 AM

$QNRX pos

1 · Reply

TwongStocks Jul. 7 at 10:20 PM

0 · Reply

Pipelinepivots Jul. 7 at 4:01 AM

Good luck traders I like the stocks tagged and keep an eye on SSY , small caps are HOT SSY is a textbook low-float sleeper with a catalyst. No dilution. Micro float. Merger with Regional Health is still in motion and the market’s ignoring it. These are the types of plays that go from dead quiet to 300%+ in a blink. You either see it early or chase it late. $GNS $IFBD $TIRX $QNRX

0 · Reply

Pipelinepivots Jul. 5 at 8:31 PM

SSY is being slept on. Tiny float. No dilution. Under $1. There’s a major merger in the works and barely anyone’s watching. When these setups move, they don’t walk they rip. The chart is coiled, and all it needs is volume. $IFBD $QNRX $APRN $VEEE

0 · Reply

rockytoday Jul. 3 at 4:39 PM

$QNRX buy the dip

0 · Reply

magic2007 Jul. 3 at 2:23 PM

$QNRX So I invested 7k way back, and now I see I have 14 shares. Wow, I guess I ride it out..

2 · Reply

Kevin73ca Jun. 26 at 5:34 PM

$QNRX 20k shares available borrow free 49 percent at

0 · Reply

Kevin73ca Jun. 26 at 3:09 PM

$CYN watch $QNRX this is also next

0 · Reply

prismmarketview Jun. 26 at 2:37 PM

$QNRX “It’s not just a skin disease—it can be life-threatening.” Quoin Pharmaceuticals (Nasdaq: QNRX) spotlights the urgent pediatric need in Netherton Syndrome in a powerful new NETHERTON NOW episode featuring leading dermatologist Prof. Jemima Mellerio. Don’t miss this expert perspective on the fight to bring treatments to children who need them mosthttps://prismmarketview.com/quoin-pharmaceuticals-highlights-urgent-pediatric-need-in-netherton-syndrome-with-new-expert-video/

0 · Reply

StayPresent Jun. 25 at 11:18 PM

$QNRX should be OTC. China dog💩

1 · Reply

Yuyus Jun. 25 at 11:36 AM

$QNRX Quoin Pharmaceuticals Secures FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome June 24, 2025

0 · Reply

prismmarketview Jun. 24 at 1:35 PM

$QNRX https://prismmarketview.com/quoin-pharmaceuticals-secures-fda-rare-pediatric-disease-designation-for-qrx003-in-netherton-syndrome/

0 · Reply

volatilelt Jun. 24 at 12:58 PM

$QNRX Let's have +50% day - thats about time have a payday for long time investors

0 · Reply

OpenOutcrier Jun. 24 at 12:41 PM

$QNRX (+13.1% pre) Quoin Pharmaceuticals Ltd (QNRX) Granted FDA Rare Pediatric Disease Designation for QRX003 https://ooc.bz/l/68433

0 · Reply

Market Cap	4.81M
Revenue (ttm)	0.00
Net Income (ttm)	-8.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,069
Avg Vol	213,068
Day's Range	N/A - N/A
Shares Out	588,000.00
Stochastic %K	0%
Beta	1.47
Analysts	Strong Sell
Price Target	$50.00